Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

36.95 -0.88 (-2.31%)

Streaming Delayed Price Updated: 1:42 PM EDT, May 15, 2026 Add to My Watchlist

Price and Volume

Volume	509,265
Open	37.51
Bid (Size)	36.94 (100)
Ask (Size)	36.97 (200)
Prev. Close	37.83
Today's Range	36.92 - 37.90
52wk Range	10.63 - 41.00
Shares Outstanding	128,000,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Indivior to Participate in Upcoming Investor Conferences

May 14, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗

May 11, 2026

Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.

Via The Motley Fool

Performance

YTD	+3.4%	+3.4%
1 Month	+12.1%	+12.1%
3 Month	+9.5%	+9.5%
6 Month	+23.9%	+23.9%
1 Year	+235.0%	+235.0%

More News

Indivior Announces $175 Million Accelerated Share Repurchase

May 04, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior (INDV) Q1 2026 Earnings Transcript ↗

May 01, 2026

Via The Motley Fool

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗

April 30, 2026

Via Chartmill

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗

April 21, 2026

Via Chartmill

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

April 30, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

April 24, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

April 16, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

April 09, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗

February 26, 2026

Via Chartmill

INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case ↗

February 20, 2026

Via Chartmill

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

March 31, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

March 17, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

March 12, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior Announces Proposed Convertible Senior Notes Offering

March 12, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

March 11, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Divisadero Dumps Stride Stock ↗

March 06, 2026

Via The Motley Fool

Indivior (INDV) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Via The Motley Fool

Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

February 26, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior to Participate in Upcoming Investor Conferences

February 24, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet ↗

February 22, 2026

Via The Motley Fool

Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth ↗

February 22, 2026

Via The Motley Fool

Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio ↗

February 22, 2026

Via The Motley Fool

Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround ↗

February 22, 2026

Via The Motley Fool

Frequently Asked Questions

Is Indivior Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Indivior Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Indivior Pharmaceuticals, Inc. - Common Stock trade on?

Indivior Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock is INDV on the Nasdaq Stock Market

What is the current price of Indivior Pharmaceuticals, Inc. - Common Stock?

The current price of Indivior Pharmaceuticals, Inc. - Common Stock is 36.95

When was Indivior Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Indivior Pharmaceuticals, Inc. - Common Stock was at 05/15/26 01:42 PM ET

What is the market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock is 4.73B

How many shares of Indivior Pharmaceuticals, Inc. - Common Stock are outstanding?

Indivior Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.